KI2011 is a novel potent FLT3 tyrosine kinase inhibitor in acute myeloid leukemia cells with FLT3-mutation

被引：0
|
作者：
Ryu, Hwani [1 ]
Song, Jie-Young [1 ]
Ahn, Jiyeon [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Seoul, South Korea
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-806
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
806
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
    Stone, R. M.
    Mandrekar, S. J.
    Sanford, B. L.
    Laumann, K.
    Geyer, S.
    Bloomfield, C. D.
    Thiede, C.
    Prior, T. W.
    Doehner, K.
    Marcucci, G.
    Lo-Coco, F.
    Klisovic, R. B.
    Wei, A.
    Sierra, J.
    Sanz, M. A.
    Brandwein, J. M.
    de Witte, T.
    Niederwieser, D.
    Appelbaum, F. R.
    Medeiros, B. C.
    Tallman, M. S.
    Krauter, J.
    Schlenk, R. F.
    Ganser, A.
    Serve, H.
    Ehninger, G.
    Amadori, S.
    Larson, R. A.
    Doehner, H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05): : 454 - 464
  • [42] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Zhang, Yvyin
    Wang, Peihong
    Wang, Yang
    Shen, Yang
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [43] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Yvyin Zhang
    Peihong Wang
    Yang Wang
    Yang Shen
    Biomarker Research, 11
  • [44] THE FLT3 TYROSINE KINASE AS A THERAPEUTIC TARGET IN ACUTE MYELOBLASTIC LEUKEMIA
    Griffin, J.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 23
  • [45] FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia
    Grunwald, Michael R.
    Levis, Mark J.
    SEMINARS IN HEMATOLOGY, 2015, 52 (03) : 193 - 199
  • [46] FLT3 TYROSINE KINASE DOMAIN (TKD) MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Markova, J.
    Michkova, P.
    Maaloufova, J.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 550 - 550
  • [47] Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication
    Mead, Adam J.
    Gale, Rosemary E.
    Kottaridis, Panagiotis D.
    Matsuda, Satomi
    Khwaja, Asim
    Linch, David C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) : 454 - 460
  • [48] Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase
    Komeno, Y
    Kurokawa, M
    Imai, Y
    Takeshita, M
    Matsumura, T
    Kubo, K
    Yoshino, T
    Nishiyama, U
    Kuwaki, T
    Kubo, K
    Osawa, T
    Ogawa, S
    Chiba, S
    Miwa, A
    Hirai, H
    LEUKEMIA, 2005, 19 (06) : 930 - 935
  • [49] Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
    Heidel, F
    Solem, FK
    Breitenbuecher, F
    Lipka, DB
    Kasper, S
    Thiede, MH
    Brandts, C
    Serve, H
    Roesel, J
    Giles, F
    Feldman, E
    Ehninger, G
    Schiller, GJ
    Nimer, S
    Stone, RM
    Wang, YF
    Kindler, T
    Cohen, PS
    Huber, C
    Fischer, T
    BLOOD, 2006, 107 (01) : 293 - 300
  • [50] Real-World Use of FLT3 Tyrosine Kinase Inhibitors in Patients with Relapsed/Refractory FLT3 mutation-Positive Acute Myeloid Leukemia in the United States
    Grinblatt, David L.
    Han, Wei
    Nimke, David
    Feng, Qi
    Sullivan, Loretta
    Pandya, Bhavik J.
    BLOOD, 2021, 138
12345